Corvus Pharmaceuticals, Inc. (CRVS)

Import this data to Google Sheets with:

=jivedata("CRVS","financials")

Full statements spill as a table. For one cell: =jivedata("CRVS","Revenue") or =jivedata("CRVS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Corvus Pharmaceuticals, Inc.

CRVS • CIK 0001626971

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-23,407	$-27,548	$-42,971	$-56,963
Investment Income, Net	—	$1,824	$2,505	$5,172
Gain (Loss) on Disposition of Property Plant Equipment	$22	$5	$5	$5
Fair Value Adjustment of Warrants	—	$33,377	$-27,141	$-27,141
Rental Income, Nonoperating	—	$78	—	$78
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	$-27,029	$-59,096	$-13,325	$-51,791
Income (Loss) from Equity Method Investments	—	$-3,197	$-1,958	$-2,338
Net Income (Loss) Attributable to Parent	$-27,029	$-62,293	$-15,283	$-54,129
Weighted Average Number of Shares Outstanding, Basic	48,025,274	60,985,165	78,964,842	95,187,741
Weighted Average Number of Shares Outstanding, Diluted	48,025,274	60,985,165	79,742,685	94,409,898
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-27,433	$-62,614	$-14,891	$-54,274
Research and Development Expense	$16,526	$19,385	$33,719	$45,532
General and Administrative Expense	$6,881	$8,163	$9,252	$11,431
Operating Expenses	$23,407	$27,548	$42,971	$56,963
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	$66	$65	$-17	$-796
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$-470	$-386	$409	$651

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$12,620	$8,740	$4,576	$18,905
Debt Securities, Available-for-sale, Current	—	—	$52,174	$196,323
Property, Plant and Equipment, Net	$236	$151	$220	$830
Accounts Receivable, after Allowance for Credit Loss, Current	$26	$75	$37	$6
Operating Lease, Right-of-Use Asset	$1,149	$1,177	$839	$659
Equity Method Investments	$16,123	$12,540	$10,991	$15,107
Prepaid Expense and Other Assets, Current	$781	$2,368	$1,427	$5,731
Other Assets, Noncurrent	$89	$632	$855	$1,713
Assets, Current	$27,956	$54,407	$58,214	$220,965
Assets	$45,553	$68,907	$71,119	$239,274
Operating Lease, Liability, Noncurrent	$1,373	$937	$534	$274
Liabilities	$6,869	$36,339	$9,914	$13,946
Accounts Payable, Current	$1,525	$2,582	$2,491	$4,047
Operating Lease, Liability, Current	$1,374	$185	$403	$454
Accrued Liabilities, Current	—	$3,725	$6,486	$9,171
Warrants and Rights Outstanding	—	$28,910	$28,910	$3,781
Liabilities, Current	$6,869	$35,402	$9,380	$13,672
Preferred Stock, Value, Issued	—	$0	—	$0
Common Stock, Value, Issued	$5	$7	$7	$8
Additional Paid in Capital	—	—	$474,387	$670,557
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-967	$-1,288	$-896	$-1,293
Retained Earnings (Accumulated Deficit)	$-334,717	$-397,010	$-412,293	$-443,944
Stockholders' Equity Attributable to Parent	$38,684	$32,568	$61,205	$225,328
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	290,000,000	290,000,000	290,000,000	290,000,000
Common Stock, Shares, Issued	49,038,582	67,899,779	74,696,629	84,120,944

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-539	$-3,880	$-4,164	$4,214
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$12,620	$8,740	$4,576	$39,679
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-27,029	$-62,293	$-15,283	$-54,129
Net Cash Provided by (Used in) Operating Activities	$-23,935	$-25,424	$-32,797	$-44,529
Payments to Acquire Debt Securities, Available-for-sale	$47,048	$70,119	$91,750	$254,044
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	$62,623	$42,630	$84,128	$117,193
Payments to Acquire Property, Plant, and Equipment	$34	$34	$174	$698
Proceeds from Sale of Property, Plant, and Equipment	$22	$5	$5	$5
Net Cash Provided by (Used in) Investing Activities	$15,541	$-27,484	$-7,796	$-142,549
Proceeds from Issuance of Common Stock	$31,989	$16,405	$16,405	—
Proceeds from Issuance of Warrants	—	$8,934	$8,934	$8,934
Proceeds from Warrant Exercises	—	$18,590	$35,745	$35,745
Proceeds from Other Equity	—	$7,843	$7,843	$7,843
Proceeds from Stock Options Exercised	$12	$68	$684	$1,885
Net Cash Provided by (Used in) Financing Activities	$7,855	$49,028	$36,429	$191,292
Conversion of Stock, Amount Issued	—	$13,401	$1,769	$1,769
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	—	—	$1,211	$1,211
Depreciation, Depletion and Amortization	$151	$85	$105	$117
Accretion (Amortization) of Discounts and Premiums, Investments	—	$1,141	$1,345	$552
Share-based Payment Arrangement, Noncash Expense	$2,147	$3,003	$5,330	$8,082
Fair Value Adjustment of Warrants	—	$33,377	$-27,141	$-27,141
Income (Loss) from Equity Method Investments	—	$-3,197	$-1,958	$-2,338
Increase (Decrease) in Prepaid Expense and Other Assets	$8	$1,587	$-941	$4,444
Increase (Decrease) in Other Noncurrent Assets	$-40	$28	$-338	$-353
Increase (Decrease) in Other Current Assets	—	$543	$223	$1,087
Increase (Decrease) in Accounts Payable	$-451	$1,057	$-91	$910
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	$-3,578	$-245	$2,761	$4,158
IncreaseDecreaseInOperatingLeaseLiability	—	$-252	$-185	$-355

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("CRVS","financials")

Full statements spill as a table. For one cell: =jivedata("CRVS","Revenue") or =jivedata("CRVS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.